Previous Close | 8.00 |
Open | 8.00 |
Bid | 7.65 |
Ask | 9.65 |
Strike | 350.00 |
Expire Date | 2025-01-17 |
Day's Range | 8.00 - 8.00 |
Contract Range | N/A |
Volume | |
Open Interest | 378 |
(Bloomberg) -- The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.Most Read from BloombergChina’s Ultra-Rich Gen Zs Flock Home as Global Tensions RiseEx-Goldman Bankers Make a Fortune With Controversial Bet on CoalTreasuries Halt Fed-Fueled Rout as Stocks Struggle: Markets WrapMcCarthy Ambushed as Republican Hardliners Change Course on Spending PlanIndia S
Based on analysts' projections, you might think the pharmaceutical giant isn't worth investing in right now.
Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.